


PHARMACEUTICAL 2020

CONTRAFECT Corp Rank 154 of 362





PHARMACEUTICAL 2020

CONTRAFECT Corp Rank 154 of 362

The relative strengths and weaknesses of CONTRAFECT Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CONTRAFECT Corp compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 227% points. The greatest weakness of CONTRAFECT Corp is the variable Revenues, reducing the Economic Capital Ratio by 108% points.

The company's Economic Capital Ratio, given in the ranking table, is -128%, being 175% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	30,760
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,058
Liabilities, Non-Current	3,337
Other Assets	3,149
Other Compr. Net Income	30
Other Expenses	0
Other Liabilities	6,069
Other Net Income	15,072
Property and Equipment	1,100
Research and Development	18,057
Revenues	0
Selling, General and Administrative Expense	9,809

Output Variable	Value in 1000 USD
Assets	35,009
Liabilities	19,464
Expenses	27,866
Stockholders Equity	15,545
Net Income	-12,794
Comprehensive Net Income	-12,779
Economic Capital Ratio	-128%